摘要
目的观察米氮平治疗糖尿病并抑郁症的疗效及对血糖的影响。方法60例糖尿病并抑郁症患者随机分成2组，每组30例。研究组在常规降糖药治疗基础上联用米氮平（15～45mg／d）治疗，对照组仅用降糖药治疗，疗程12周。采用汉米顿抑郁量表（HAMD）及副反应量表（TESS）于治疗前和治疗后1、2、4、6、8、12周末各评定一次，并定期测定空腹血糖、餐后2h血糖及糖化血红蛋白，对所有数据采用spss11.5软件包进行统计和t检验。结果经12周治疗后，研究组HAMD评分、血糖（BG）及糖化血红蛋白（HbA1c）水平下降，与对照组比较有显著性差异（P〈0．001或P〈0．05）。结论米氮平治疗糖尿病并抑郁症疗效显著，并能改善血糖的控制水平。
Objective To investigate the curative effects of mirtazapine on diabetes with de- pression and its influence on blood glucose. Methods Sixty cases of diabetes and depression were randomly divided into two groups. The study group with the conventional treatment of hypoglycemic agents on the basis of combined mirtazapine （15-45 mg/d） treatment,the control group with only hypoglycemic drug treatment for 12 weeks. HAMD and TESS were used to assess before and at 1,2,4,6,8 and 12 weeks after treatment. The regularly tests FBG, 2 hPBG and HbA1c, for all of the data were used spss 11.5 package statistics and t-test. Results After 12 weeks treatment,HAMD score, glucose and HbA1c in study group decreased compared with the control group and there were significant differences（P〈0. 001 or P〈0.05）. Conclusion Mirtazapine treatment of diabetes and depression is effective and could improve the control levels of blood glucose.
出处
《实用临床医学（江西）》
CAS
2008年第11期16-18,共3页
Practical Clinical Medicine
关键词
米氮平
糖尿病
抑郁症
mirtazapine
diabetes
depression
